ipl-logo

Case Study: Janssen Pharmaceutica '

1472 Words6 Pages

Janssen Pharmaceutica
Janssen is one of the world’s leading research based pharmaceutical organisations and is part of the Johnson and Jonson family of companies. J&J is a diverse group of healthcare specialists. Johnson and Johnson was founded in 1886 and is an American pharmaceutical, medical devices and consumer packages goods manufacture. Janssen Pharmaceutical Companies of Johnson & Johnson, is dedicated to research and development of new drugs against the most important unmet medical needs of this generation, including oncology, infectious disease, neuroscience, cardiovascular and metabolic diseases and immunology.
In 1953 Janssen was founded by Paul Janssen. The company was founded within his father Constant Janssen’s company N.V. Produkten …show more content…

There is large investments being made in new technology to reduce production times and improve quality so that patients receive the best quality products in the swiftest manner. Patient care is at the heart of Janssen as clinical trials are on site to always try to gain more information on the potential products to improve.
Janssen is a subsidiary of Johnson & Johnson, so to look at the organisation structure it must fall under J&J’s structure first. J&J’s organisation can be split into three main factions; Consumer healthcare, medical devices and pharmaceuticals.
Consumer healthcare is concerned with J&J’s baby care, skin care, oral care and woman’s health care products. It also takes into account over-the counter pharmaceuticals, nutritional products and wellness and prevention programs.
Medical devices is a business segment that produces a broad range of innovative products and solutions used primarily by health care professionals in the fields of orthopaedics, aesthetics, vision care, cardiovascular disease, infection prevention, diabetes care, and neurological disease. This segment is comprised of Global Medical Solutions, Global Orthopaedics and Neurological, and Global Surgery …show more content…

This is the fraction Janssen falls under. Within the J&J company, Janssen is split into seven subsidiaries; Janssen, Janssen R&D LLC, Janssen Pharmaceuticals Inc., Janssen Healthcare Innovation, Janssen Diagnostics, Janssen Therapeutics and Janssen Scientific affairs. Each of these fractions are responsible for different products produced by Janssen Pharmaceutica, e.g. Janssen Therapeutics is concerned with the development of diagnostic solutions for oncology, infectious diseases, central nervous system diseases and immunologic and cardio vascular disease.
Janssen’s headquarters are still in Beerse, Belgium since the beginning of the company. Principal Subsidiaries to note of Janssen are Janssen Pharmaceutica Inc. (United States); Janssen Pharmaceutica N.V./Janssen Research Foundation (Belgium); Xian-Janssen Pharmaceutical Co. Ltd. (China).; Janssen-Cilag N.V. (Belgium); Johnson & Johnson Pharm. Partners (Puerto Rico); Janssen-Ortho Inc. (Canada); Ortho-McNeil Pharmaceutical Inc. (United States); Ortho Biotech Inc. (United States); Janssen-Cilag

Show More
Related

  • Xacc/280 Week 3 Risk Analysis For Healthcare

    484 Words  | 2 Pages

    The total cost of computer hardware and software is accounted for within the capital expenditures in the healthcare organization’s financial budget and can be reduced over years to come. Receiving in-kind donations, contributions, or grants should be figured in for this classification, with the price of the donations being the main factor. Also, there might be a labor factor that should be calculated in to establish the overall acquisition cost. Since, technology requests usually demand specialized expertise and knowledge, colleagues of the technological team or external consultants might be required as essential participant of the process, but this would include an opportunity expense or a total consulting expense.

    Read More

  • Examples Of Medical Advances In The 1920s

    1284 Words  | 6 Pages

    One of the most overlooked medical devices of our time was invented in the 1920s. It is commonly found in households all across the world and prevents infections. Band Aids were invented by a man who cared deeply for his wife’s wellbeing. “Earle Dickson (1892–1961), a cotton buyer for Johnson & Johnson, developed the Band-Aid while trying to make a convenient, easy-to-apply bandage for his wife, Josephine, who was prone to many minor cuts and burns in the family kitchen (Routledge 6)”. His optimism would lead to him selling the rights to a company that would globalize the product.

    Read More

  • The Pros And Cons Of The Pharmaceutical Industry

    1631 Words  | 7 Pages

    Nowadays it seems like legal drugs are more expensive than illegal ones. This dilemma occurs because the pharmaceutical industry affects the economy significantly. Although the United States is a mixed market economy, there are instances where the economy seems like a free market economy. A free market economy allows companies to determine the prices of goods free from government intervention. The pharmaceutical industry, despite several regulations set by the food and drug administration, is a free market economy.

    Read More

  • Business Case Study: Jurlique International Pty Ltd.

    2179 Words  | 9 Pages

    The native German couple relocated to a farm in the Adelaide Hills a year prior to the launch of their brand, due to its warm climate. Jurgen was a biochemist and naturopath, who had previously worked for German holistic skincare brand Dr. Hauschka. Ulrike was a horticulturalist and botanist. The Klein 's 153 acre 'biodynamic ' farm is still part of the Jurlique Company. Today Jurlique claims

    Read More

  • Dr. Edwin Wiley Grove: A Brief Biography

    512 Words  | 3 Pages

    The Paris Medicine company marketed Febrile, Grove's Tasteless Chill Tonic, cold tablets and other products. The Tasteless Quinine Company was soon established in Asheville, North Carolina. Dr. Grove had many interest in Asheville, including the famous Grove Park Inn. He died in 1927. The Paris Medicine Company was renamed Grove Laboratories in 1935.

    Read More

  • Managed Care Essay

    885 Words  | 4 Pages

    Hospital and continuing to help increase patient flow and help increase their financial gain. Consequently, leading to higher medical cost for patients and insurance companies. The market of healthcare in the U.S is rapidly evolving and becoming more complex mostly due to the delivery of health care becoming corporatized by the help of IDSs and

    Read More

  • Healthcare Disparities In Health

    898 Words  | 4 Pages

    The government has strived to achieve equity in access and provided a comprehensive range of affordable and quality care. At the same time, it has not neglected services that are in the realm of public goods. The importance of quality and standards of care is without question. Important quality and innovation will attract inward investment and generate income to the nation through many opportunities in the health sector and industry e.g. health tourism, but pose challenges in marketing and branding. The MOH has an established and transparent quality assurance programme but this is not the case in the private sector.

    Read More

  • Case Study Global Product Roll Out

    1051 Words  | 5 Pages

    They didn’t want to lose out on any profits by going global. Since they were new to this line of business they partner with J&J’s McNeil division. J&J were an excellent choice to partner with to introduce Benecol to the global market. The only hurdles stopping Benecol to be introduced into the world were regulatory issues. It would be difficult to bring Benecol to the market as quickly as possible in Europe and even more so in US.

    Read More

  • Biopharm-Seltek Negotiation Case Study

    1888 Words  | 8 Pages

    On day two, we are assigned the “The Biopharm- Seltek Negotiation” role play. After the “Salary Negotiation” on the first day with a desirable outcome, we thought that we would perform better because we seemed to be more familiar with the negotiation process. The feeling of confidence then came into my mind, which made me believe that we would achieve a very favorable deal today. However, compared to other groups’ outcomes, we realized that it was not. Let us recall what had happened today and then analyse to find out why the outcome was not as good as we had expected and how to improve our shortcomings.

    Read More

  • Johnson & Johnson Value Chain Analysis Summary

    942 Words  | 4 Pages

    Research and development is a very important part of their value chain. It is linked throughout almost every aspect of their priority topics including product quality, reliability, and safety, access and affordability, and all the way to their product end of life. Research and development at Johnson & Johnson is used to create new products and figure out ways to improve their old products. Since there are many illnesses that do not have a cure, Johnson & Johnson invests in

    Read More

  • Johnson & Johnson Case Analysis

    1623 Words  | 7 Pages

    Background and Introduction: Johnson & Johnson is an American multinational organization that was founded in 1886. This company consists of pharmaceutical and consumer packaged goods. Johnson & Johnson has been headquartered in New Jersey. This organization has operations on over 57 countries and their products are sold on over 175 countries. Their calendar has a worldwide sale of $65 billion for 2011.

    Read More

  • Pharmacology Case Study

    443 Words  | 2 Pages

    Pharmacology Assignment Week 4 Marty Smith is a 67-year-old male who has called 911 after experiencing chest pain and dizziness. The paramedics arrive and notice a bottle of nitroglycerin on the table. The patient states he has angina and is to take the medication as needed for chest pain. He took one pill an hour ago and a second pill 10 minutes prior to calling 911.

    Read More

  • Johnson International Corporation: Case Analysis: Johnson International Corporation

    800 Words  | 4 Pages

    Johnson International Corporation (JIS) is a global company that offers logistical support to the military and private companies which employs 100 people and it is largely located in US, Europe and Far East. It has been doing business for last 15 years and it had a net income after tax of $10 million. 70 % of their business is related to military sector and its focus is to provide logical support to military and private sector. In this company the president and chief executive officer were the same person and he/she was responsible for the overall activities of the company. The company has cut the budget in various field including the budget in IT capital and human resource which includes training for employee.

    Read More

  • Porter's Five Forces Analysis Pharmaceutical Industry

    720 Words  | 3 Pages

    PORTERS FIVE FORCES ANALYSIS - PHARMA INDUSTRY Using Porter's Five Forces we can analyse the scope of the pharmaceutical industry. It looks into five factors namely, competitive rivalry, threat of new entrants, threat of substitute products, bargaining power of suppliers and bargaining power of customers. " Competitive rivalry: The pharmaceutical industry is highly fragmented with almost 3,000 pharma companies and 10,500 manufacturing units. Due to increasing demand of high-quality drugs, low-to-moderate entry barrier to the new entrant, the presence of a number of large and small firm this market is highly competitive.

    Read More

  • Rorer Converts-Poulenc Case Study

    2104 Words  | 9 Pages

    INTRODUCTION The latter decade of the 20th century brought a number of major innovations to the pharmaceutical industry, most notably a remarkable wave of successful joint ventures and mergers between big and medium players in the market. In this case study we analyzed the Rorer and Rhône-Poulenc (RP) merger in July 31, 1990 that created a major multinational company: the Rhône-Poulenc Rorer, Inc. (RPR), where the RP became the majority shareholder, owning 68 percent of the RPR’s shares. Prior to the merger, Rorer lacked the resources to access the European market, and the firm presented relatively low cash balance and rising debt which, according to financial analysts, appeared to be handicapping its strategy of growth by acquisitions.

    Read More

More about Case Study: Janssen Pharmaceutica '

Open Document